Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known 09/719,410 Application Number INFORMATION DISCLOSURE December 12, 2000 Filing Date STATEMENT BY APPLICANT First Named Inventor **Burkhard Goke** Art Unit 1623 (Use as many sheets as necessary) Examiner Name A. Mohamed 0206-UTL-9 Sheet 1 of | 2 Attorney Docket Number

**U.S. PATENT DOCUMENTS** Name of Patentee or Applicant of Likaminer Cinitials Document Number Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appen Publication Date MM-DD-YYYY Cite No.1 Cited Document (if known) Number US-USus-US-US-US US-US-US US-US-US-US-US-US-US-US-US-ÚS-کلا

BADEN

FOREIGN PATENT DOCUMENTS						
Examiner Cite		Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Initials*	No. 1 Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known) Poblication Date MM-DD-YYYY Document		Passages or Relevant Figures Appear	T⁵		
						ļ
	<b>_</b>					
	<b> </b>	<b>-</b>				<b> </b>
	<u> </u>	<del> </del>				
	<del></del>				<u> </u>	

Examiner Signature	Abdel A. Mohame	Date Considered	04/1	3/0	5

\*EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FEB 2 2 2005 Under the Paper

PTO/SB/08b(08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Will Reduction Act 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

HAILER Substitute for form 1449B/PTO Complete if Known Application Number 09/719,410 INFORMATION DISCLOSURE Filing Date December 12, 2000 STATEMENT BY APPLICANT First Named Inventor **Burkhard Goke** Art Unit 1623 (Use as many sheets as necessary) A. Mohamed Examiner Name 2 0206-UTL-9 2 Attorney Docket Number Sheet

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
AM	1	D'ALESSIO, D. A., et al., "Elimination of the Action of Glucagon-Like Peptide-1 Causes an Impairment of Glucose Tolerance After Nutrient Ingestion by Healthy Baboons" JOURNAL OF CLINICAL INVESTIGATION, (Jan 1998) 97 (1) 133-138.			
AN	2	RITZEL, U., et al., "A Synthetic Glucagon-Like Peptide-1 Analog With Improved Plasma Stability" JOURNAL OF ENDOCRINOLOGY, (Oct 1998) Bristol, GB, 159 (1) 93-102.			
AM	3	SCHIRRA, J., et al., "Exendin (9-39) Amide is an Antagoinist of Glucagon-Like Peptide-1 (7-38) Amide in Humans" JOURNAL OF CLINICAL INVESTIGATION (Apr 1998) 101 (7) 1421-1430.			
, 					
		·			

Signature M5dll M-1 Mondand Considered 0//15/01	Examiner Signature		Date Considered	04/13/0	7]
---	-----------------------	--	--------------------	---------	----

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

<sup>\*</sup>EXAMINER: Initial if reterence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.